Terms: = Lung cancer AND TPM3, ENSG00000143549, 7170
49 results:
1. Cost-Effectiveness of Comprehensive Genomic Profiling in Patients With Non-Small Cell lung cancer for the Colombian Health System.
Gamboa O; Bonilla CE; Quitian D; Torres GF; Buitrago G; Cardona AF
Value Health Reg Issues; 2024 Jan; 39():115-125. PubMed ID: 38101152
[TBL] [Abstract] [Full Text] [Related]
2. CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations.
Li W; Fei K; Guo L; Wang Y; Shu C; Wang J; Ying J
J Thorac Oncol; 2024 Apr; 19(4):613-625. PubMed ID: 38070598
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic assessment of lung adenocarcinoma patients with early-staging diseases: a nomogram based on coagulation-related factors.
Wu LL; Lin WK; Qian JY; Ma SS; Li MJ; Li K; Li ZX; Lan G; Xie D
Eur J Cardiothorac Surg; 2023 Nov; 64(5):. PubMed ID: 37699000
[TBL] [Abstract] [Full Text] [Related]
4. Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice.
Vingiani A; Lorenzini D; Conca E; Volpi CC; Trupia DV; Gloghini A; Perrone F; Tamborini E; Dagrada GP; Agnelli L; Capone I; Busico A; Pruneri G
Cancer Biomark; 2023; 38(3):301-309. PubMed ID: 37545217
[TBL] [Abstract] [Full Text] [Related]
5. CANTRK: A Canadian Ring Study to Optimize Detection of NTRK Gene Fusions by Next-Generation RNA Sequencing.
Stockley TL; Lo B; Box A; Corredor AG; DeCoteau J; Desmeules P; Feilotter H; Grafodatskaya D; Greer W; Hawkins C; Huang WY; Izevbaye I; Lépine G; Martins Filho SN; Papadakis AI; Park PC; Riviere JB; Sheffield BS; Spatz A; Spriggs E; Tran-Thanh D; Yip S; Zhang T; Torlakovic E; Tsao MS
J Mol Diagn; 2023 Mar; 25(3):168-174. PubMed ID: 36586421
[TBL] [Abstract] [Full Text] [Related]
6. MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC.
Tyler LC; Le AT; Chen N; Nijmeh H; Bao L; Wilson TR; Chen D; Simmons B; Turner KM; Perusse D; Kasibhatla S; Christiansen J; Dudek AZ; Doebele RC
Thorac Cancer; 2022 Nov; 13(21):3032-3041. PubMed ID: 36101520
[TBL] [Abstract] [Full Text] [Related]
7. [Establishment of artificial neural network model for predicting lymph node metastasis in patients with stage Ⅱ-Ⅲ gastric cancer].
Xue Z; Lu J; Lin J; Huang CM; Li P; Xie JW; Wang JB; Lin JX; Chen QY; Zheng CH
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Apr; 25(4):327-335. PubMed ID: 35461201
[No Abstract] [Full Text] [Related]
8. Development and Validation of an Immune-Based Prognostic Risk Score for Patients With Resected Non-Small Cell lung cancer.
He L; Huang Y; Chen X; Huang X; Wang H; Zhang Y; Liang C; Li Z; Yan L; Liu Z
Front Immunol; 2022; 13():835630. PubMed ID: 35401554
[TBL] [Abstract] [Full Text] [Related]
9. Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers.
Ukkola I; Nummela P; Kero M; Tammio H; Tuominen J; Kairisto V; Kallajoki M; Haglund C; Peltomäki P; Kytölä S; Ristimäki A
Virchows Arch; 2022 Apr; 480(4):807-817. PubMed ID: 35237889
[TBL] [Abstract] [Full Text] [Related]
10. Primary NTRK-rearranged Spindle Cell Neoplasm of the lung: A Clinicopathologic and Molecular Analysis of 3 Cases.
Zhu P; Wang J
Am J Surg Pathol; 2022 Jul; 46(7):1007-1013. PubMed ID: 35220354
[TBL] [Abstract] [Full Text] [Related]
11. Adult NTRK-rearranged spindle cell neoplasms of the viscera: with an emphasis on rare locations and heterologous elements.
Tsai JW; Lee JC; Hsieh TH; Huang SC; Lee PH; Liu TT; Kao YC; Chang CD; Weng TF; Li CF; Lin JC; Liang CW; Su YL; Chang IY; Wang YT; Chang NY; Yu SC; Wang JC; Huang HY
Mod Pathol; 2022 Jul; 35(7):911-921. PubMed ID: 35149769
[TBL] [Abstract] [Full Text] [Related]
12. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
[TBL] [Abstract] [Full Text] [Related]
13. ROS1 rearrangements in non-small cell lung cancer: screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performance.
Prall OWJ; Browning J; Nastevski V; Caporarello S; Bates B; Hewitt CA; Arenas A; Lamb G; Howlett K; Arnolda R; Adeloju R; Stuart S; Xu H; Fellowes A; Fox SB
Pathology; 2022 Apr; 54(3):279-285. PubMed ID: 34635319
[TBL] [Abstract] [Full Text] [Related]
14. Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population.
Zhao R; Yao F; Xiang C; Zhao J; Shang Z; Guo L; Ding W; Ma S; Yu A; Shao J; Zhu L; Han Y
J Pathol Clin Res; 2021 Jul; 7(4):375-384. PubMed ID: 33768710
[TBL] [Abstract] [Full Text] [Related]
15. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
[TBL] [Abstract] [Full Text] [Related]
16. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
[TBL] [Abstract] [Full Text] [Related]
17. Minimal Residual Disease Monitoring Using a 3'ALK Universal Probe Assay in ALK-Positive Anaplastic Large-Cell Lymphoma: ddPCR, an Attractive Alternative Method to Real-Time Quantitative PCR.
Quelen C; Grand D; Sarot E; Brugières L; Sibon D; Pradines A; Laurent C; Brousset P; Lamant L
J Mol Diagn; 2021 Feb; 23(2):131-139. PubMed ID: 33246076
[TBL] [Abstract] [Full Text] [Related]
18. A Case of Simultaneously Diagnosed lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation.
Zhao S; Liu W; Li S; Shi T; Chen Q; Li Q; Sun L; Ren D; Song Z; Huang C; Xu S
Cancer Res Treat; 2021 Apr; 53(2):601-606. PubMed ID: 33091968
[TBL] [Abstract] [Full Text] [Related]
19. Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.
Cui M; Han Y; Li P; Zhang J; Ou Q; Tong X; Zhao R; Dong N; Wu X; Li W; Jiang G
Mol Oncol; 2020 Nov; 14(11):2787-2795. PubMed ID: 32871626
[TBL] [Abstract] [Full Text] [Related]
20. NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.
Leal JL; Peters G; Szaumkessel M; Leong T; Asadi K; Rivalland G; Do H; Senko C; Mitchell PL; Quing CZ; Dobrovic A; Thapa B; John T
Lung Cancer; 2020 Aug; 146():154-159. PubMed ID: 32540558
[TBL] [Abstract] [Full Text] [Related]
[Next]
